News Releases

BEDFORD, Mass., June 5, 2026 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention...

Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational...

BEDFORD, Mass., April 15, 2026 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first...

BEDFORD, Mass., April 3, 2026 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention...

Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2...

BEDFORD, Mass. — February 18, 2026 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin,...

BEDFORD, Mass., February 12, 2026 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth...

Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive Officer Cheryl Blanchard to Become Executive Chair of the Board of...

Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA...

BEDFORD, Mass., November 5, 2025 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module...